Tilray announced an investment of US$32.6M to increase the company’s Canadian cannabis production and manufacturing footprint by 203,000 square feet across three facilities. This investment will expand Tilray’s total production and manufacturing footprint from 1.1 million to 1.3 million square feet worldwide.
High Park Gardens – Leamington, Ontario
In 2019, Tilray acquired Natura Naturals, now operating as High Park Gardens. "High Park Gardens is a 662,000 square-foot cultivation facility, of which 155,000 square feet is currently operational and licensed for cannabis cultivation and manufacturing," the team with the company explains. "As a result of the investment announced today, High Park Gardens will add an additional 127,000 square feet of production space. Once the expansion is complete and licensed by Health Canada, High Park Gardens’ footprint will increase by 82 percent, utilizing up to 282,000 square feet of cultivation space with room to expand further in the future. The expansion project is expected to create more than 40 job opportunities over the course of the next year."
High Park Processing Facility – London, Ontario
In June 2018, Tilray announced that High Park Holdings would establish a manufacturing facility to produce adult-use cannabis products in London, Ontario. "Currently High Park London is a 56,000 square foot facility licensed by Health Canada to process and sell adult-use cannabis products. As a result of the investment announced today, High Park London will double in size from 56,000 square feet to 112,000 square feet. The expansion project will enhance the site’s R&D, processing and packaging capabilities and is expected to generate 60 additional jobs," they explain.
Tilray Canada – Nanaimo, British Columbia
Tilray Canada is the company’s GMP-certified R&D, cultivation and processing facility located in Nanaimo, British Columbia. The facility began operating in April 2014 and was one of the first to be awarded a license by Health Canada to cultivate medical cannabis. Tilray utilizes this facility to produce pharmaceutical-grade medical cannabis products for Canada as well as international markets. As a result of the investment announced today, the Nanaimo facility will increase its footprint from 60,000 square feet to 80,000 square feet.
For more information: